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Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape
Town, South AfricaTwo million children were infected with multidrug-
resistant (MDR) Mycobacterium tuberculosis strains, and 25,000
children developed MDR tuberculosis (MDR-TB) in 2014
according to a recent estimate. MDR-TB (i.e., resistance
against at least isoniazid and rifampicin) is a microbiological
diagnosis, but TB is only bacteriologically confirmed in 30–
40% of children with TB from whom specimens are obtained.
Children, therefore, should also be presumptively diagnosed
with MDR-TB if their source cases have MDR-TB. New geno-
typic diagnostic tests are helpful for rapid identification of
MDR-TB, and the World Health Organization (WHO) has also
recently approved second-line drug susceptibility testing by
line-probe assay to assist in rapid diagnosis of extensively
drug-resistant TB.
Treatment outcomes in children with MDR-TB are better
(80–90% treatment success) than those of adults (50–60%
treatment success). However, current treatment regimens still
include use of a daily second-line injectable drug for
4–8 months. The WHO now also recommends a 9- to
12-month shortened regimen for adults and children with
rifampicin monoresistant TB and those with strictly MDR-
TB (no other resistance). This shorter regimen includes newer
generation fluoroquinolones and clofazimine. Repurposed
and new anti-TB drugs and regimens are currently being
evaluated in adults with MDR-TB. Once found to be effica-
cious in adults, efficacy studies do not have to be repeated
in children; however, dose-determination and safety studies
are still essential in children, not only for the new drugs,but also for existing second-line drugs. The aim is to develop
a shorter, injection-free regimen for children with MDR-TB.
Although children experience fewer adverse effects from
second-line anti-TB drugs than those experienced by adults,
adverse effects remain a challenge. These need to be
addressed for improved safety and better adherence.
Prevention of MDR-TB is better than cure. Although many
experts agree that treatment of MDR infection in high-risk
contacts (children <5 years and HIV-infected people) is
needed, current guidelines vary widely in their recommenda-
tions, from no treatment to three-drug preventive therapy.
Three prospective randomized control studies are ongoing
or planned to identify a single-drug treatment of MDR-TB
infection.
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